Clinical Trial Update: A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD [Phase 3]

View source ↗

Summary

Phase 3 trial update indicating Flutiform is well tolerated and effective in chronic obstructive pulmonary disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• FlutiForm (fluticasone propionate/formoterol)

Snippet

Sponsor: Mundipharma Research Limited | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED